Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Marinus Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Marinus Pharmaceuticals's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 52.2% per year.
Anahtar bilgiler
-14.7%
Kazanç büyüme oranı
18.7%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | 52.2% |
Özkaynak getirisi | n/a |
Net Marj | -493.1% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price
Sep 20Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Gelir ve Gider Dağılımı
Marinus Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 30 | -149 | 66 | 0 |
31 Mar 24 | 28 | -145 | 65 | 0 |
31 Dec 23 | 31 | -141 | 61 | 0 |
30 Sep 23 | 31 | -134 | 60 | 3 |
30 Jun 23 | 26 | -29 | 59 | 3 |
31 Mar 23 | 22 | -35 | 60 | 0 |
31 Dec 22 | 25 | -20 | 57 | 0 |
30 Sep 22 | 20 | -14 | 55 | 0 |
30 Jun 22 | 28 | -105 | 49 | 0 |
31 Mar 22 | 28 | -91 | 39 | 0 |
31 Dec 21 | 15 | -99 | 37 | 0 |
30 Sep 21 | 15 | -88 | 31 | 0 |
30 Jun 21 | 5 | -84 | 28 | 0 |
31 Mar 21 | 4 | -76 | 26 | 0 |
31 Dec 20 | 2 | -76 | 19 | 0 |
30 Sep 20 | 0 | -74 | 16 | -2 |
30 Jun 20 | 0 | -72 | 14 | -18 |
31 Mar 20 | 0 | -69 | 13 | -9 |
31 Dec 19 | 0 | -54 | 12 | 0 |
30 Sep 19 | 0 | -49 | 11 | 10 |
30 Jun 19 | 0 | -46 | 11 | 36 |
31 Mar 19 | 0 | -43 | 9 | 33 |
31 Dec 18 | 0 | -37 | 9 | 28 |
30 Sep 18 | 0 | -31 | 8 | 23 |
30 Jun 18 | 0 | -24 | 8 | 17 |
31 Mar 18 | 0 | -19 | 7 | 12 |
31 Dec 17 | 0 | -19 | 7 | 12 |
30 Sep 17 | 0 | -20 | 7 | 13 |
30 Jun 17 | 0 | -22 | 7 | 15 |
31 Mar 17 | 0 | -27 | 7 | 20 |
31 Dec 16 | 0 | -29 | 7 | 22 |
30 Sep 16 | 0 | -30 | 6 | 24 |
30 Jun 16 | 0 | -29 | 6 | 22 |
31 Mar 16 | 0 | -25 | 6 | 19 |
31 Dec 15 | 0 | -25 | 6 | 19 |
30 Sep 15 | 0 | -21 | 6 | 15 |
30 Jun 15 | 0 | -18 | 5 | 13 |
31 Mar 15 | 0 | -17 | 4 | 12 |
31 Dec 14 | 0 | -13 | 3 | 9 |
30 Sep 14 | 0 | -12 | 2 | 8 |
30 Jun 14 | 0 | -12 | 2 | 7 |
31 Mar 14 | 0 | -11 | 2 | 6 |
Kaliteli Kazançlar: MRNS is currently unprofitable.
Büyüyen Kar Marjı: MRNS is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MRNS is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Büyüme Hızlandırma: Unable to compare MRNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: MRNS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Özkaynak Getirisi
Yüksek ROE: MRNS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.